

D Paul Harkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11036875/publications.pdf>

Version: 2024-02-01

61
papers

8,568
citations

101384

36
h-index

128067

60
g-index

62
all docs

62
docs citations

62
times ranked

14168
citing authors

#	ARTICLE	IF	CITATIONS
1	5-Fluorouracil: mechanisms of action and clinical strategies. <i>Nature Reviews Cancer</i> , 2003, 3, 330-338.	12.8	4,015
2	The Role of BRCA1 in the Cellular Response to Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1659-1668.	3.0	399
3	BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. <i>Cancer Research</i> , 2003, 63, 6221-8.	0.4	339
4	Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw199.	3.0	338
5	BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 7413-7420.	3.2	200
6	Molecular Basis for Estrogen Receptor \hat{A} Deficiency in BRCA1-Linked Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1683-1694.	3.0	183
7	Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue. <i>Journal of Clinical Oncology</i> , 2011, 29, 4620-4626.	0.8	178
8	RNA expression analysis from formalin fixed paraffin embedded tissues. <i>Histochemistry and Cell Biology</i> , 2008, 130, 435-445.	0.8	169
9	Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. <i>Oncologist</i> , 2010, 15, 390-404.	1.9	155
10	BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. <i>Oncogene</i> , 2001, 20, 6123-6131.	2.6	154
11	BRCA1 , a Potential Predictive Biomarker in the Treatment of Breast Cancer. <i>Oncologist</i> , 2007, 12, 142-150.	1.9	146
12	Identification of a BRCA1-mRNA Splicing Complex Required for Efficient DNA Repair and Maintenance of Genomic Stability. <i>Molecular Cell</i> , 2014, 54, 445-459.	4.5	146
13	<scp>BRCA</scp>1, a \hat{C} complex \hat{A} ™ protein involved in the maintenance of genomic stability. <i>FEBS Journal</i> , 2015, 282, 630-646.	2.2	141
14	BRCA1 : mechanisms of inactivation and implications for management of patients. <i>Lancet, The</i> , 2002, 360, 1007-1014.	6.3	115
15	BRD7, a Subunit of SWI/SNF Complexes, Binds Directly to BRCA1 and Regulates BRCA1-Dependent Transcription. <i>Cancer Research</i> , 2010, 70, 2538-2547.	0.4	115
16	BRCA1 Deficiency Exacerbates Estrogen-Induced DNA Damage and Genomic Instability. <i>Cancer Research</i> , 2014, 74, 2773-2784.	0.4	94
17	Identification and Validation of an Anthracycline/Cyclophosphamide \hat{A} -Based Chemotherapy Response Assay in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt335.	3.0	91
18	The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. <i>Cancer Research</i> , 2002, 62, 2644-9.	0.4	82

#	ARTICLE	IF	CITATIONS
19	Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer. <i>Laboratory Investigation</i> , 2018, 98, 15-26.	1.7	81
20	The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export. <i>Nucleic Acids Research</i> , 2017, 45, 12816-12833.	6.5	79
21	BRCA1 and implications for response to chemotherapy in ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 113, 134-142.	0.6	78
22	BRCA1 and c-Myc Associate to Transcriptionally Repress Psoriasin, a DNA Damage-Inducible Gene. <i>Cancer Research</i> , 2005, 65, 10265-10272.	0.4	76
23	Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 5502-5502.	0.8	71
24	BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 721-731.	1.1	68
25	BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 123, 492-498.	0.6	62
26	BRCA1 Regulates the Interferon β -mediated Apoptotic Response. <i>Journal of Biological Chemistry</i> , 2002, 277, 26225-26232.	1.6	60
27	The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. <i>Histopathology</i> , 2014, 65, 340-352.	1.6	59
28	The Complex Relationship between BRCA1 and ER \pm in Hereditary Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1514-1518.	3.2	58
29	Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM. <i>Cancer Research</i> , 2015, 75, 2159-2165.	0.4	58
30	The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon- β -mediated apoptosis. <i>Oncogene</i> , 2005, 24, 5492-5501.	2.6	53
31	Uncovering Functionally Relevant Signaling Pathways Using Microarray-Based Expression Profiling. <i>Oncologist</i> , 2000, 5, 501-507.	1.9	47
32	BRCA1 Interacts with and Is Required for Paclitaxel-Induced Activation of Mitogen-Activated Protein Kinase Kinase Kinase 3. <i>Cancer Research</i> , 2004, 64, 4148-4154.	0.4	46
33	BRCA1 Regulates IFN- β Signaling through a Mechanism Involving the Type I IFNs. <i>Molecular Cancer Research</i> , 2007, 5, 261-270.	1.5	44
34	BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers. <i>Nucleic Acids Research</i> , 2013, 41, 8601-8614.	6.5	44
35	Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis. <i>Nucleic Acids Research</i> , 2011, 39, 9536-9548.	6.5	43
36	NF- κ B is a critical mediator of BRCA1-induced chemoresistance. <i>Oncogene</i> , 2014, 33, 713-723.	2.6	41

#	ARTICLE	IF	CITATIONS
37	TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.. <i>Oncotarget</i> , 2014, 5, 1609-1620.	0.8	37
38	The \hat{I}^{Np63} Proteins Are Key Allies of BRCA1 in the Prevention of Basal-Like Breast Cancer. <i>Cancer Research</i> , 2011, 71, 1933-1944.	0.4	35
39	BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. <i>Journal of Pathology</i> , 2012, 227, 200-208.	2.1	33
40	PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. <i>Journal of Pathology</i> , 2011, 224, 564-574.	2.1	32
41	High <i>EMSY</i> expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. <i>Cancer</i> , 2019, 125, 2772-2781.	2.0	28
42	Analysis of <i>wntless</i> (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. <i>Modern Pathology</i> , 2015, 28, 428-436.	2.9	27
43	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. <i>European Urology</i> , 2017, 72, 509-518.	0.9	26
44	BRCA1—A good predictive marker of drug sensitivity in breast cancer treatment?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006, 1766, 205-216.	3.3	25
45	Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. <i>Oncotarget</i> , 2018, 9, 4722-4736.	0.8	22
46	Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line. <i>Nucleic Acids Research</i> , 2016, 44, e137-e137.	6.5	20
47	Dual roles of DNA repair enzymes in RNA biology/post-transcriptional control. <i>Wiley Interdisciplinary Reviews RNA</i> , 2016, 7, 604-619.	3.2	19
48	Generation of a non-small cell lung cancer transcriptome microarray. <i>BMC Medical Genomics</i> , 2008, 1, 20.	0.7	18
49	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. <i>Gut</i> , 2019, 68, 1918-1927.	6.1	18
50	Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors. <i>Cancer Research</i> , 2022, 82, 819-830.	0.4	16
51	PICan: An integromics framework for dynamic cancer biomarker discovery. <i>Molecular Oncology</i> , 2015, 9, 1234-1240.	2.1	15
52	The identification of a novel role for BRCA1 in regulating RNA polymerase I transcription. <i>Oncotarget</i> , 2016, 7, 68097-68110.	0.8	15
53	Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 247-258.	2.9	14
54	The molecular and genetic basis of inherited cancer risk in Gynaecology. <i>The Obstetrician and Gynaecologist</i> , 2015, 17, 233-241.	0.2	8

#	ARTICLE	IF	CITATIONS
55	Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention. <i>Oncotarget</i> , 2015, 6, 43244-43254.	0.8	8
56	Implications for Powering Biomarker Discovery Studies. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 130-139.	1.2	7
57	Genomics and the Impact of New Technologies on the Management of Colorectal Cancer. <i>Oncologist</i> , 2006, 11, 988-991.	1.9	5
58	Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification. <i>Clinical Cancer Research</i> , 2022, 28, 3546-3556.	3.2	5
59	Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment. <i>BMJ Open</i> , 2018, 8, e023115.	0.8	3
60	BRCA1 and BRCA2: Role in the DNA Damage Response, Cancer Formation and Treatment. , 2009, , 415-443.		2
61	The biology of breast carcinoma. <i>Cancer</i> , 2003, 98, 1327-1328.	2.0	1